Do elevated plasma S100A12 levels predict atherosclerosis in peritoneal dialysis patients?

References

• Krediet RT, Balafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol. 2010;6(8):451–460
   PubMed Web of Science ®Google Scholar
• Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycolisation and the pathogenesis of diabetic complications. Ann Intern Med. 1984;101:527–537
   PubMed Web of Science ®Google Scholar
• Heidland A,Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 2001;38:S100–S106
   PubMed Web of Science ®Google Scholar
• Zeier, M.,Schwenger V, Deppisch R. Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int. 2003;63:298–305
   PubMed Web of Science ®Google Scholar
• Leurs P, Lindholm B. The AGE-RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease. Arch Med Res. 2013;44:601–610
   PubMed Web of Science ®Google Scholar
• Park S, Yoon SJ, Tae HJ, et al. RAGE and cardiovascular disease. Front Biosci. 2011;16:486–497
   Web of Science ®Google Scholar
• Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol. 2013;94:55–68
   PubMed Web of Science ®Google Scholar
• Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev. 2001;17:436–443
   PubMed Web of Science ®Google Scholar
• Selvin E, Halushka MK, Rawlings AM, et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013;62:2116–2121
   PubMed Web of Science ®Google Scholar
• Mori Y, Kosaki A, Kishimoto N, et al. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol. 2009;9:18–24
   Google Scholar
• Yang Z, Yan WX, Cai H, et al. S100A12 provokes mast cell activation: A potential amplification pathway in asthma and innate immunity. J Allergy Clin Immunol. 2007;119:106–114
   PubMed Web of Science ®Google Scholar
• Mahajan N, Malik N, Bahl A, et al. Receptor for advanced glycation end products RAGE)and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis. 2009;207:597–602
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949–955
   PubMed Web of Science ®Google Scholar
• Basta G, Sironi AM, Lazzerini G, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006;91:4628–4634
   PubMed Web of Science ®Google Scholar
• Peiskerová M, Kalousová M, Danzig V, et al. Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease—A prospective observational study. BMC Nephrol. 2013;14:142
   PubMedGoogle Scholar
• Zakiyanov O, Kalousová M, Kříha V, et al. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease. Kidney Blood Press Res. 2011;34:457–464
   PubMed Web of Science ®Google Scholar
• Kalousova M, Hodkova M, Kazderova M, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. 2006;47:406–411
   PubMed Web of Science ®Google Scholar
• Gohda T, Tanimoto M, Moon JY, et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract. 2008;81:196–201
   PubMed Web of Science ®Google Scholar
• Koyama H, Shoji T, Fukumoto S, et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol. 2007;27:147–153
   PubMed Web of Science ®Google Scholar
• Kalousová M, Kuběna AA, Benáková H, et al. EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) and mortality of long-term hemodialysis patients: A prospective observational cohort study. Clin Biochem. 2012;45:556–560
   PubMed Web of Science ®Google Scholar
• Nakashima A, Carrero JJ, Qureshi AR, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:213–219
   Google Scholar
• Shiotsu Y, Mori Y, Nishimura M, et al. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(4):718–723
   PubMed Web of Science ®Google Scholar
• Kim JK, Park S, Lee MJ, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012;220(1):208–214
   PubMed Web of Science ®Google Scholar
• Uchiyama-Tanaka Y, Mori Y, Kosaki A, et al. Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease. Ther Apher Dial. 2008;12:28–32
   PubMed Web of Science ®Google Scholar
• Isoyama N, Leurs P, Qureshi AR, et al. Plasma S100A12 and soluble receptor of advanced glycationend product levels and mortality in chronic kidney disease Stage 5 patients. Nephrol Dial Transplant. 2015;30:84–91
   PubMed Web of Science ®Google Scholar
• Foell D, Ichida F, Vogl T, et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet. 2003;361:1270–1272
   PubMed Web of Science ®Google Scholar
• Kallinich T,Wittkowski H, Keitzer R, et al. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis. 2010;69:677–682
   PubMed Web of Science ®Google Scholar
• Wittkowski H, Hirono K, Ichida F, et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum. 2007;56:4174–4181
   PubMed Web of Science ®Google Scholar
• Foell D, Kane D, Bresnihan B, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford). 2003;42:1383–1389
   PubMed Web of Science ®Google Scholar
• Kosaki A, Hasegawa T, Kimura T, et al. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;9:5423–5428
   Google Scholar
• Basta G, Leonardis D, Mallamaci F, et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int. 2010;77:225–231
   PubMed Web of Science ®Google Scholar
• Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med. 1998;4:1025–1031
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A, Denner L, Schrijvers BF, et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes. 2004;53(1):166–172
   PubMed Web of Science ®Google Scholar
• Wendt T, Harja E, Bucciarelli L, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis. 2006;85:70–77
   Google Scholar
• Koyama H, Nishizawa Y. AGEs/RAGE in CKD: Irreversible metabolic memory road toward CVD? Eur J Clin Invest. 2010;40:623–635
   PubMed Web of Science ®Google Scholar
• Miranda LP, Tao T, Jones A, et al. Total chemical synthesis and chemotactic activity of human S100A12 (EN-RAGE). FEBS Lett. 2001;488:85–90
   PubMed Web of Science ®Google Scholar
• Foell D, Kucharzik T, Kraft M,et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847–853
   PubMed Web of Science ®Google Scholar
• Moroz OV, Antson AA, Dodson EJ, et al. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr. 2002;58(part 3):407–413
   PubMedGoogle Scholar
• Foell D, Wittkowski H, Hammerschmidt I, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 2003;50:1286–1295
   Web of Science ®Google Scholar
• Komatsuda A, Ohtani H, Wakui H, et al. Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis. Clin Nephrol. 2006;66:315–321
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – An inflammatory disease. N Engl J Med. 1999;340:115–126
   PubMed Web of Science ®Google Scholar
• Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135–2150
   PubMed Web of Science ®Google Scholar